Interleukin-2-based therapies in cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 36350987.
- Also identified by DOI 10.1126/scitranslmed.abo5409.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Molecular insights into the mechanism of beneficial and adverse effects of interleukin-2 (IL-2) have resulted in the development of improved IL-2 formulations with IL-2 receptor bias and tissue-targeting properties. Several of these compounds are currently in clinical development and are ushering IL-2 therapy into the current era of cancer immunotherapy.
Medical subject headings
- Interleukin-2
- Neoplasms